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Using chemogenomics, Summers et al.
identify PfAcAS as the target of two
antimalarial compounds, MMV019721
and MMV084978. PfAcAS is an essential,
nuclear-localized enzyme responsible for
acetyl-CoA biosynthesis in blood-stage
parasites. Both compounds inhibit
PfAcAS competitively and act by
depleting acetyl-CoA and disrupting
histone acetylation in the parasite.d.
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https://doi.org/10.1016/j.chembiol.2021.07.010SUMMARYWe identify the Plasmodium falciparum acetyl-coenzyme A synthetase (PfAcAS) as a druggable target, using
genetic and chemical validation. In vitro evolution of resistancewith two antiplasmodial drug-like compounds
(MMV019721 and MMV084978) selects for mutations in PfAcAS. Metabolic profiling of compound-treated
parasites reveals changes in acetyl-CoA levels for both compounds. Genome editing confirms thatmutations
in PfAcAS are sufficient to confer resistance. Knockdown studies demonstrate that PfAcAS is essential for
asexual growth, and partial knockdown induces hypersensitivity to both compounds. In vitro biochemical as-
says using recombinantly expressed PfAcAS validates that MMV019721 and MMV084978 directly inhibit the
enzyme by preventing CoA and acetate binding, respectively. Immunolocalization studies reveal that PfAcAS
is primarily localized to the nucleus. Functional studies demonstrate inhibition of histone acetylation in com-
pound-treated wild-type, but not in resistant parasites. Our findings identify and validate PfAcAS as an
essential, druggable target involved in the epigenetic regulation of gene expression.INTRODUCTION
Despite significant gains in global malaria control efforts over the
last decade, there are over 200 million new cases each year and
nearly 500,000 deaths, primarily in young children in Africa
(WHO, 2019). Resistance has emerged to most approved drugsCell Chemical Biology 29, 1–11, F
This is an open access article undand its spread may undermine the gains seen over the last
decade. New drugs are urgently needed and a concerted effort
by many in the field has resulted in the screening of over 5 million
small molecules in phenotypic assays to assess parasite killing
(Gamo et al., 2010; Guiguemde et al., 2010; Plouffe et al.,
2008). These efforts have identified thousands of new chemicalebruary 17, 2022 ª 2021 The Authors. Published by Elsevier Ltd. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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prevention, Cell Chemical Biology (2021), https://doi.org/10.1016/j.chembiol.2021.07.010scaffolds. A major goal of new drug development for malaria is
the discovery of compounds that kill parasites in multiple stages
of the life cycle and, thus, could be used both in disease
prevention and treatment. The Malaria Drug Accelerator (MalDA)
consortiumwas convened to address the problem of target iden-
tification with an initial focus on chemogenomic approaches. We
recently reported the screening of over 500,000 compounds for
liver-stage activity and identification of hundreds of chemical
scaffolds with liver-stage activity (Antonova-Koch et al., 2018).
We subjected a subset of the available compounds to further
analysis, including metabolomic profiling, additional phenotypic
screening of blood-stage parasites, testing for cross-resistance,
and in vitro evolution of drug resistance.
Many antimalarial molecules have been identified by whole-
cell phenotypic screens, and most currently used antimalarial
drugs were developed without precise knowledge of the drug
target. However, many compounds with activity in phenotypic
screens have subsequently been found to target one of a hand-
ful of common pathways in the parasite (e.g., hemoglobin
degradation, mitochondrial function, and cellular homeostasis),
that are susceptible to common resistance mechanisms (e.g.,
mutations in PfCRT, PfMDR1, PfATP4, or PfDHODH) (Van Voo-
rhis et al., 2016; Allman et al., 2016; Antonova-Koch et al., 2018;
Creek et al., 2016). The development of drug candidates with
novel modes of action requires the knowledge of the com-
pound’s target. Furthermore, the identification and validation
of new druggable targets enables modern therapeutic develop-
ment strategies to be applied to malaria. Modern target-based
drug discovery approaches can provide access to screening
vast chemical diversity (for instance, via DNA-encoded
libraries) to identify new chemical scaffolds, and to optimize
potency and selectivity versus the human enzyme (via struc-
ture-guided drug design and biochemical assays of enzyme ac-
tivity). Applying modern therapeutic development strategies to
targets validated from phenotypic screens can complement
earlier approaches and provides an accelerated path to malaria
drug discovery.
MMV019721 and MMV084978 were chosen for further anal-
ysis because of promising characteristics: both compounds
were active against multiple parasite life-cycle stages (liver and
asexual blood stages) indicating the potential for both chemo-
prophylactic and curative therapeutic application, and neither
compoundwas cross-resistant with previously identified targets,
suggesting that they targeted a new pathway. Here, we present
target identification and validation studies revealing the acetyl-
coenzyme A synthetase (PfAcAS; PF3D7_0627800) as the target
of both MMV019721 and MMV084978. Acetyl-CoA synthetases
catalyze the condensation of acetate and CoA into acetyl-CoA,
which is a key cellular metabolite essential to cell survival.
Here, we demonstrate that inhibition of PfAcAS results in rapid
cell death, disrupts intracellular acetyl-CoA levels, and provides
strong evidence for the essentiality of this enzyme for parasite
survival. In vitro biochemical validation studies confirm PfAcAS
as the target of MMV019721 and MMV084978. PfAcAS is
localized to the nucleus of the parasite, and mechanistic studies
show that inhibition of PfAcAS results in a reduction in histone
acetylation. The work presented here identifying and validating
PfAcAS enables next-generation drug discovery for this essen-
tial enzyme.2 Cell Chemical Biology 29, 1–11, February 17, 2022RESULTS
MMV019721 and MMV084978 are effective inhibitors of
asexual- and liver-stage growth
Recent high-throughput whole-cell screens have identified a
number of small molecules active against Plasmodium species
(Antonova-Koch et al., 2018; Delves et al., 2018; Van Voorhis
et al., 2016). Of particular interest are molecules that inhibit
multiple life-cycle stages and can therefore function as both
a curative therapeutic for blood-stage infection, but also act
as prophylactic and/or transmission-blocking therapy. To
identify molecules with prophylactic potential, recent screens
have employed a P. berghei model system to screen for com-
pounds with activity during liver-stage infection (Antonova-
Koch et al., 2018). Two small molecules, MMV019721 and
MMV084978, emerged from these screens and were selected
for target identification efforts within the MalDA consortium
(Figure 1A). MMV019721 has modest activity against blood-
stage parasites in vitro (P. falciparum 3D7 half-maximal
effective concentration [EC50] = 460 ± 100 nM) and against
liver-stage P. berghei parasites (Pbluc EC50 = 2,100 ±
770 nM). MMV084978 demonstrated similar in vitro efficacy
(P. falciparum Dd2 EC50 = 150 ± 36 nM) with increased liver-
stage potency (Pbluc EC50 = 520 ± 210 nM). Neither molecule
was active against HepG2 cells, indicating a promising lack of
mammalian cell cytotoxicity (HepG2 EC50 > 50 mM for both
compounds).
MMV019721 and MMV084978 target acetyl-coA
biosynthesis
A robust strategy for discovering the targets of cell-active com-
pounds is in vitro evolution of resistance andwhole-genome anal-
ysis, which has successfully identified the targets of many novel
antimalarials discovered in phenotypic screens (Luth et al.,
2018). To identify the target of MMV019721 and MMV084978,
we conducted in vitro evolution experiments to select for resistant
parasites by either a continuous or pulsed exposure to 33 or 43
EC50 concentrations of each compound (Table S1). Across 12 in-
dependent selections with MMV019721, bulk parasite popula-
tions with 3- to 18-fold resistance were obtained, and clones
were isolated by limiting dilution. The resistant clones isolated
upon exposure to MMV019721 showed an average 12-fold shift
in the EC50 (range: 3.5- to 21-fold) (Figure 1B; Table S1). Whole-
genome sequencing of 14 clones (1 or 2 each from 9 independent
selections) revealed that all resistant lines carried single-nucleo-
tide variants in a common gene, PF3D7_0627800, which codes
for aputativeacetyl-CoA-CoAsynthetase (PfAcAS) (Figure1A;Ta-
bles S1 and S2). Five clones harbored a mutation resulting in an
A597V amino acid change with an average 15-fold shift in EC50
over wild-type parasites (Dd2 EC50 = 400 ± 72 nM, PfAcAS:
A597V-resistant clone EC50 = 7,700 ± 570 to 11,000 ± 1,300 nM;
Figure 1B; Table S1). Six clones carried a T648M mutation and a
slightly higher resistance phenotype of 17- to 21-fold increase
over wild-type (PfAcAS:T648M EC50 = 6,800 ± 420 to 8,400 ±
1,400 nM; Figure 1B; Table S1). Two clones with low levels of
resistance (3.5-fold over wild-type parasites) were found to
possess amplification across a region of chromosome 6 contain-
ingPfAcASand threeother genes: the ribonucleasePprotein sub-
unit p29 (PF3D7_0627900), 6-pyruvoyltetrahydropterin synthase
Figure 1. Mutations in the P. falciparum
acetyl-CoA synthetase (PfAcAS) confer resis-
tance to MMV019721 and MMV084978
(A) Homology modeling of PfAcAS reveal that
mutations identified in parasites resistant to
MMV019721 or MMV084978 line the predicted
active site of the enzyme.
(B and C) The in vitro susceptibility of representative
drug-resistant cloned parasite lines identified as
carrying mutations in PfAcAS by WGS. Data repre-
sent the mean + standard deviation (SD) of four ex-
periments conducted in triplicate for MMV019721,
and themean + SD of two experiments conducted in
triplicate for MMV084978.
(D) Representative dose-response assays for the
3D7 (light blue) and Dd2 (dark blue) parent lines,
resistance-selected clones carrying A597V (purple)
or T648M (light green), and CRISPR-Cas9 gene-
edited parasites bearing A597V (red) or T648M (dark
green). Shown is one representative biological
replicate experiment run with technical triplicates.
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(PF3D7_0628100) (Figure S1; Table S3).
Selections with MMV084978 yielded four clones ranging in
resistance phenotype from 2.4- to 25-fold over wild-type para-
sites (Figure 1C; Table S1). Individual clones had one of three
different mutations in the PfAcAS gene, resulting in either an
A597V, Y607C, or A652S amino acid change (Figure 1A; Table
S2). Interestingly, the A597V mutation was identified in highly
resistant lines in both compound selections, and similar muta-
tions at position 652 (A652T or A652S in MMV019721 and
MMV084978 selections, respectively) were seen in lines with in-
termediate levels of resistance to both compounds.
A further four clones with low-level resistance to MMV019721
(2- to 3-fold) lacked mutations in PfAcAS but were found to
possess mutations in acyl-CoA synthetase 11 (ACS11; T767I,
S74L, D269G, and an indel L24-D30; Figure S2; Tables S1
and S2). None of the resistance-associated mutations in
ACS11 occurred near the predicted active site of the proteinCell Che(Figure S2A). Mutations in ACS11 have pre-
viously been associated with resistance
to CoA-biosynthesis targeting antiplasmo-
dial pantothenamides (Schalkwijk et al.,
2019), and other structurally unrelated anti-
plasmodial compounds MMV019719 and
MMV665924 (Cowell et al., 2018), suggest-
ing that this locus may be a non-specific
drug resistance mediator.
Metabolomic profiling implicates
PfAcAS inhibition in drug mode of
action
To confirm our in vitro evolution results
indicating that these molecules both target
PfAcAS, we profiled the cellular metabolo-
mic response to drug exposure for each
compound and evaluated whether similarmetabolic signatures were observed. Previous studies have iden-
tified distinct metabolomic profiles for antimalarials of known
mechanism of action (Allman et al., 2016). Magnetically purified
3D7 parasites were incubated in the presence of each drug at
10-fold their reported EC50 value for 2.5 h (Allman et al., 2016).
Principal-component analysis of metabolite profiles (Chong
et al., 2019; Chong and Xia, 2018) indicates that the metabolic
response to these compounds is distinct from known antimalarial
drug responses, such as mitochondrial inhibitors (e.g., atova-
quone, ELQ-300, and DSM1) or folate biosynthesis inhibitors
(e.g., pyrimethamine, P218, andWR99210), andPfATP4 inhibitors
(e.g., SJ733, NITD609, and KAF246) (Figures 2 and S3). Full
analysis of the metabolic profile defined the major effects of
MMV019721 and MMV084978 as a significant decrease in the
levels of acetyl-CoA, N-carbamoyl-L-aspartate, dihydroorotate,
and orotate (Figures S3C and S3D; Table S4). While not statisti-
cally significant, general nucleotide levels were increased in com-




































Figure 2. MMV019721 and MMV084978 induce unique cellular me-
tabolomic profiles in P. falciparum parasites upon drug exposure
Principal-component analysis (PCA) plot of the metabolic profiles of parasites
treated with MMV019721 or MMV084978, in comparison to those of anti-
plasmodial compounds known to target mitochondrial function (atovaquone,
ELQ-300, and DSM1, green), folate biosynthesis (pyrimethamine, P218, and
WR99210, blue), or ion homeostasis (PfATP4-SJ733, NITD609, or KAF246,
cyan) (Allman et al., 2016). PC1 represented 50.6% variance while PC2 rep-
resented 20.4% of the variance between all compounds. Principal compo-
nents were calculated using the log2 fold-change in abundance of 98 soluble
metabolites caused by test compounds relative to untreated parasite controls.
PCAwas conducted withMetaboAnalystR (Chong et al., 2019; Chong and Xia,
2018). See also Figure S3 and Table S4.
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tate, dihydroorotate, and orotate, provided a unique metabolic
profile (Figures 2 and S3) for both compounds.Allelic replacement studies demonstrate that PfAcAS
mutations are sufficient for resistance to MMV019721
and MMV084978
To investigate the contributions of specific alleles, we intro-
duced individual resistance mutations into an otherwise








MMV019721 400 ± 58 (n = 3) 400 ± 72 (n = 4)
MMV084978 110 ± 28 (n = 3) 150 ± 36 (n = 4)
Mefloquine 18 ± 4.6 (n = 5) 15 ± 5.7 (n = 4)
Atovaquone 0.42 ± 0.05 (n = 3) 0.30 ± 0.13 (n = 4)
Dihydroartemisinin 2.6 ± 1.6 (n = 3) 4.6 ± 3.0 (n = 5)
Amodiaquine 7.4 ± 1.8 (n = 5) 19 ± 6.0 (n = 4)
Data presented as mean ± SD with n bioreplicate assays.
aSD, standard deviation.
4 Cell Chemical Biology 29, 1–11, February 17, 2022ogy-driven repair with donor repair templates. The A597V and
T648M PfAcAS alleles were introduced into Dd2 parasites
and their resistance phenotypes assessed. Both edited cell
lines recapitulated the phenotype of the respective drug-
selected clones (Figure 1D; Table 1), validating these muta-
tions as sufficient to confer resistance to MMV019721 and
MMV084978. Cross-resistance experiments further demon-
strated that either A597V or T648M mutation was sufficient
to confer cross-resistance to both compounds. This provides
further evidence that PfAcAS is the molecular target of these
compounds.PfAcASknockdown results in parasite growth arrest and
demonstrates differential sensitivity toMMV019721 and
MMV084978
It is possible that the mutations we discovered and genetically
validated encode drug resistance genes rather than mutations
that directly impede the target-inhibitor interaction. To assess
whether the PfAcAS enzyme is critical for parasite survival and
whether it is a candidate for therapeutic inhibition, we utilized
the anhydrotetracycline (aTc)-controlled TetR/DOZI–30 UTR
RNA aptamer system (Ganesan et al., 2016; Nasamu et al.,
2020) to conditionally regulate the expression levels of PfAcAS
in the context of its native promoter. To assess the knockdown
of the modified parasites, V5 and 2xHA epitope tags were fused
directly downstream of the gene. Immunoblotting confirmed
expression of an expected 117.9 kDa protein in the presence
of aTc (Figure 3A). In contrast, aTc withdrawal substantially
reduced PfAcAS levels (Figure 3A), demonstrating that efficient
knockdown had been achieved.
To determine if PfAcAS is required for survival of intra-erythro-
cytic-stage parasites, cultures were maintained in the presence
(50 and 3 nM) and absence of aTc. Analysis of growth over two
replicative cycles revealed that, while parasites maintained in
the presence of aTc were able to progress through the life cycle,
aTc withdrawal resulted in substantial growth arrest (Figure 3B).
Together, our data provide focused validation of the essentiality
of PfAcAS for parasite growth, and these are consistent with
recent genome-wide piggyBAC insertion mutagenesis (Zhang
et al., 2018) and knockout screens in P. berghei (Bushell et al.,
2017) classifying AcAS as essential.
As a further validation of this target, we determined the sensi-
tivity of the conditional knockdown parasites to MMV019721
and MMV084978. Reduction in PfAcAS expression (low aTc) re-






6,200 ± 94 (n = 4) 8,200 ± 1,700 (n = 3)
43,000 ± 6,800 (n = 3) 12,000 ± 1,200 (n = 4)
31 ± 17 (n = 4) 20 ± 11 (n = 4)
0.55 ± 0.35 (n = 4) 0.69 ± 0.38 (n = 4)
5.6 ± 3.5 (n = 4) 3.7 ± 3.0 (n = 4)




Figure 3. Conditional knockdown of PfAcAS
inhibits parasite growth and sensitizes para-
sites to MMV019721 and MMV084978
(A) Conditional knockdown (cKD) of PfAcAS
expression at reduced concentrations of aTc (3, 1, or
0 nM) over 72 h.
(B) Parasite growth over 72 h is inhibited under cKD
of PfAcAS. Shown are the average results and SD of
two independently repeated experiments with
technical replicates. **p < 0.01, Student’s t test
compared with 50 nM aTc condition.
(C and D) Susceptibility to MMV019721 and
MMV084978 was increased under conditions of
reduced PfAcAS expression. Shown is one biolog-
ical replicate run in triplicate.
(E) Average EC50 ± SD of parasite susceptibility to
MMV019721 and MMV084978 for PfAcAS cKD and
control YFP cKD lines under knockdown conditions.
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with standard aTc conditions (Figures 3C and 3D). In contrast
to the results observed with PfAcAS, conditional knockdown
of PfACS11 did not increase parasite sensitivity to either
MMV019721 or MMV084978 (Figures S2C and S2D). These
findings are consistent with MMV019721 andMMV084978 inter-
acting directly with the PfAcAS protein, while PfACS11 likely
functions as a resistance mechanism for these compounds.
Compounds directly and selectively inhibit PfAcAS
activity in vitro
Acetyl-CoA synthetase enzymes catalyze the formation of
acetyl-CoA from acetate and CoA in an ATP-dependent manner.
Homologymodeling of the P. falciparum protein using the crystal
structure of acetyl-CoA synthetase from Cryptococcus neofor-
mans H99 (PDB: 5U29) revealed that the resistance-conferring
mutations cluster around the active site of the enzyme and, in
particular, the predicted CoA binding site (Figure 1A). Mutations
conferring the highest levels of resistance to both compounds,
T648M and A597V, are predicted to occur close to the reactive
center of the enzyme and face the CoA binding site from
opposing surfaces of the protein. Together, these findings
suggest that mutations in PfAcAS may confer resistance to the
compounds by preventing drug competition with substrate and
alleviating inhibition of PfAcAS function.
To test this hypothesis, full-length recombinant wild-type
PfAcAS, T648M, and A597V proteins were expressed in Sf9 in-
sect cells and purified (Figure S4A), and their activities studied
using the EnzChek assay which measures inorganic phosphate
originated by the breakdown of the pyrophosphate released inCell Chethe first step of the PfAcAS reaction
(Webb, 1992) (Figures 4A and S5A). For
the wild-type protein, Km values of 93, 72,
and 42 mMwere obtained for ATP, acetate,
and CoA, respectively (Figure 4B; Table
S5). These values are in close relation to
those observed for the Salmonella enterica
(Reger et al., 2007), Mycobacterium
tuberculosis (Noy et al., 2014), and Homo
sapiens (Luong et al., 2000) AcAS ortho-logs. Inhibition of wild-type PfAcAS by MMV019721 and
MMV084978was tested in the presence of saturating concentra-
tions of all three substrates, ATP, acetate, and CoA, resulting in
IC50 values of 73 ± 4 and 370 ± 36 nM, respectively (Figures 4B,
4E, and 4F; Table 2).
To study the mechanisms of inhibition by MMV019721 and
MMV084978, single-inhibition measurements were performed
at fixed saturating concentrations of two of the substrates, and
variable concentrations of the third substrate. Under our exper-
imental conditions, results for MMV019721 showed a linear un-
competitive inhibition versus ATP and acetate with Ki = 200 ± 8
and 150 ± 10 nM, respectively (Figures S5C and S5D; Table
S6), and linear competitive inhibition against CoA with Ki =
22 ± 1 nM (Figures 4C and S5E; Table S6). These results suggest
that MMV019721 inhibits PfAcAS by preventing CoA from
binding to the active site. Results for MMV084978 showed linear
uncompetitive inhibition versus ATP and CoA, with Ki = 680 ± 26
and 690 ± 24 nM, respectively (Figures S5F–S5H; Table S6), and
linear mixed inhibition against acetate with Kis = 30 ± 3 nM and
Kii = 390 ± 110 nM (Figures 4D and S5G; Table S6). These results
suggest that MMV084978 inhibits PfAcAS mostly by preventing
acetate from binding to the active site; however, at higher con-
centrations, it can also inhibit the enzyme in the presence of ac-
etate, suggesting that MMV084978 is most likely not occupying
the acetate binding site.
Introduction of the A597V mutation increased the Km of the
protein for acetate by 5.5-fold (to 400 ± 12 mM), but had little or
no effect on other substrates, while the T648M mutation
increased the Km for ATP by 4.2-fold to 400 ± 17 mM (Figure 4B;
Table S5). The potency of both inhibitors was reduced againstmical Biology 29, 1–11, February 17, 2022 5
Figure 4. PfAcAS steady-state kinetics and
inhibition by MMV019721 and MMV084978
(A) PfAcAS reaction mechanism and EnzChek assay
readout.
(B) Steady-state kinetics of PfAcAS WT (circles),
A597V (triangles), and T648M (squares). Saturation
curves for ATP (orange), acetate (yellow), and CoA
(blue). Error bars indicate the SD, n = 3. Lines are the
best fit to Equations 1 (ATP and acetate) and 2 (CoA)
in the STAR Methods.
(C) Double-reciprocal plot illustrating the linear
competitive inhibition pattern obtainedwhen varying
the concentration of MMV019721 at fixed variable
concentrations of CoA and saturating concentra-
tions of ATP and acetate. Points are data obtained
with 0 (black), 20 (purple), 40 (orange), 60 (yellow),
and 80 nM (green triangles) of MMV019721. The
error bars indicate the SD, n = 3. Lines are the best fit
of the entire dataset to Equation 4.
(D) Double-reciprocal plot illustrating the linear
mixed inhibition pattern obtained when varying the
concentration of MMV084978 at fixed variable
concentrations of acetate and saturating concen-
trations of ATP and CoA. Points are data obtained
with 0 (black), 20 (purple), 40 (orange), 60 (yellow),
and 80 nM (green squares) ofMMV084978. The error
bars indicate the SD, n = 3. Lines are the best fit of
the entire dataset to Equation 5.
Saturation curves for MMV019721 (E) and
MMV084978 (F) against PfAcAS WT (black sym-
bols), A597V (dark red symbols), T648M (red
symbols), and HsAcAS (blue symbols). Error bars
indicate the SD, n = 3. Lines are the best fit to
Equation 3 and a linear fit for MMV084978 against
PfAcAS A597V (dark red line).
See also Figures S4 and S5 and Tables S5 and S6.
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increasing by 94-fold to 6.9 ± 1.2 mM, and 246-fold to 18 ±
3.2 mM for A597V and T648M, respectively (Figure 4E; Table 2).
The IC50 value for MMV084978 increased to over 100 mM for
both A597V and T648M (50% inhibition could not be obtained
at 100 mM MMV084978, >271-fold change) (Figure 4F; Table 2).
These results are consistent with parasite susceptibility observa-
tions in which the T648M mutation conferred higher levels of
resistance to MMV019721, and A597V conferred higher level
resistance to MMV084978 (Figure 1C). The effect of the A597V
mutation on the acetate Km value is also in line with the higher
fold change observed in the inhibition of PfAcAS A597V by
MMV084978, which is mostly competitive against acetate.
To assess the selectivity of these two compounds for the
Plasmodium enzyme, full-length recombinant wild-type HsAcAS
was expressed and purified (Figure S4B), and the activity was
studied using a mass spectrometry detection assay (Rapid6 Cell Chemical Biology 29, 1–11, February 17, 2022Fire), which measures the production of
acetyl-CoA. Following the determination
of the steady-state kinetic parameters (Fig-
ure S5I; Table S5), which were in close cor-
relation to values in the literature (Luong
et al., 2000), inhibition of wild-type HsAcAS
by MMV019721 and MMV084978 was
tested in the presence of the approximateKm for each substrate, resulting in an IC50 value over 100 mM
for MMV019721 and 18 mM for MMV084978 (Figures 4E and
4F; Table 2).
These results further support PfAcAS as the target of both
molecules. Moreover, both these molecules possess drug-like
properties and are amenable to medicinal chemistry optimiza-
tion, adding confidence that this enzyme is a druggable target
in Plasmodia and can be selectively inhibited.
PfAcAS localizes to the nucleus and plays a role in
histone acetylation
In other eukaryotes, subcellular localization of acetyl-CoA syn-
thetase isoforms influences their role in maintaining acetyl-CoA
pools for downstream cellular functions. To better understand
the role of PfAcAS, we determined the intracellular localization
of the PfAcAS protein by immunofluorescence assay (IFA) using
an anti-HA antibody to probe for the epitope-tagged protein.
Table 2. Inhibition of PfAcCSWT, T648MandA597V, andHsAcAS
by MMV019721 and MMV084978
Parameter AcAS MMV019721 MMV084978
IC50 (mM) WT 0.073 ± 0.004 0.37 ± 0.04
T648M 18 ± 3.2 >100
A597V 6.9 ± 1.2 >100
HsWT >100 18 ± 1.9
Hill WT 0.85 ± 0.04 0.85 ± 0.06
T648M 0.81 ± 0.12 N/Aa
A597V 0.58 ± 0.05 N/Aa
HsWT N/Aa 0.85 ± 0.07
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marker, DAPI, throughout the asexual developmental cycle,
except in late-stage parasites where labeling was observed in
punctate structures associated with the nucleus.
The localization of PfAcAS to the nucleus suggested that
PfAcAS may play a role in the recycling of acetyl-CoA from
CoA and acetate produced during the dynamic regulation of his-
tone acetylation by histone acetyltransferases (HATs) and de-
acetylases (HDACs). Inhibition of this recycling function could
deplete the nuclear store of acetyl-CoA, leading to hypoacetyla-
tion of histone proteins (Figure 5B). To test this, 24–32 h tropho-
zoite-stage parasites were exposed to 1.5, 2.5, or 5 mM
MMV019721 for a period of 3 h before isolation and analysis of
parasite lysates by semiquantitative immunoblot. In wild-type
3D7-A10 parasites, increasing concentrations of MMV019721
caused a dose-dependent reduction in acetylation of the
H4K8ac, H3K9ac, and tetra-acetylated H4 (H4Ac4) histone
markers relative to DMSO-treated controls (Figures 5C and
S6). The effect was most pronounced for H4K8ac, which is the
primary component of H4 acetylation and is a highly dynamic
marker during the blood-stage of P. falciparum (Gupta et al.,
2017). There was no effect on histone acetylation by atova-
quone, an antimalarial compound with a distinct mode of action,
while the HDAC inhibitor trichostatin A (TSA), caused a signifi-
cant increase in histone acetylation across all acetyl-histone
markers, consistent with previous studies (Andrews et al.,
2012; Gupta et al., 2017) (Figures 5C, 5D, and S6). There was
no measurable effect of these treatments on total H3
abundance.
To determine whether PfAcAS mutations, which confer
resistance to MMV019721, also protect parasites from the ef-
fect of PfAcAS inhibitors on histone acetylation, we conducted
experiments in parallel with the 3D7-T648M parasite line. At
concentrations resulting in significant histone hypoacetylation
in wild-type parasites, there was little to no measurable effect
on histone acetylation in the drug-resistant parasite line at all
but the highest concentration of MMV019721 (Figures 5C and
S6A). A similar dose-dependent reduction in histone acetyla-
tion was observed for MMV019721 in the Dd2 parent, and
protection in the Dd2-A597V-resistant line (Figures 5D and
S6B), and for MMV084978 in 3D7 and the 3D7-T648M lines
(Figures S6C and S6D). Together, these results indicate that
the effects of MMV019721 on histone acetylation were directlyassociated with PfAcAS protein inhibition, and not with off-
target effects.
In isobologram analyses, MMV019721 was strongly antago-
nistic with the HDAC inhibitor TSA, and to a lesser extent with
the HAT inhibitor garcinol (Figure S7), suggesting that the func-
tion of HDAC and HAT enzymes is dependent on PfAcAS func-
tion. Together, these findings are consistent with PfAcAS playing
an essential role in the maintenance of acetyl-CoA levels in the
nucleus. Inhibition of PfAcAS would prevent recycling of
acetyl-CoA available for histone acetylation, thereby disrupting
the epigenetic regulation of gene expression, and preventing
growth in the blood stage of the parasite.
DISCUSSION
In this study, we have identified AcAS as a druggable target in
P. falciparum. In vitro evolution of resistance experiments identi-
fied mutations in the PfAcAS gene and allelic replacement of
resistance mutations into an otherwise wild-type parasite back-
ground provided genetic validation and confirmed that eachmu-
tation inPfAcASwas sufficient to confer resistance. Experiments
using transgenic inducible knockdown parasites demonstrated
that PfAcAS is essential for asexual growth and the likely target
of MMV019721 and MMV084978. Metabolic profiling identified
changes in acetyl-CoA levels as a result of treatment and
biochemical validation demonstrated that MMV019721 and
MMV084978 directly inhibit PfAcAS by preventing CoA
and acetate binding, respectively. We also show that inhibition
by MMV019721 and MMV084978 is highly selective for the
Plasmodium enzyme compared with the human enzyme. Taken
together, these data give excellent genetic and chemical valida-
tion of PfAcAS. MMV019721 and MMV084978 are small mole-
cules with drug-like properties, suggesting that it should be
possible to develop small-molecule inhibitors of this enzyme
as potential therapeutic agents. Immunolocalization studies
indicate that PfAcAS is primarily localized to the nucleus, while
functional studies in whole cells revealed inhibition of histone
acetylation in drug-treated wild-type cells with no or limited inhi-
bition in parasites carrying either of the two major resistance
mutations.
Acetyl-CoA is central to several cellular pathways, including the
TCA cycle, and lipid and phospholipid synthesis, and it is impor-
tant to consider the impact on these pathways (Pietrocola et al.,
2015). Experimental work in other eukaryotes has documented
disruption of each of these processes (Bulusu et al., 2017; Ma-
shimo et al., 2014; Starai and Escalante-Semerena, 2004). In
those systems, there are multiple AcAS genes encoding proteins
with specific subcellular localizations associated with their pri-
mary functional role (Starai and Escalante-Semerena, 2004). In
yeast, neither of the two AcAS genes is essential, but deletion
of both is lethal (Takahashi et al., 2006). In P. falciparum there is
a single, essential AcAS gene. Recent work described a series
of panthothenamide antimetabolites that interfere with acetyl-
CoA metabolism in P. falciparum, and cause depletion of the
cellular acetyl-CoA pool (Schalkwijk et al., 2019). Metabolomic
profiling of infected red cells treated with MMV019721 or
MMV084978 similarly demonstrated a depletion of acetyl-CoA.
Interestingly, in P. falciparum, previous metabolomics work
has demonstrated that acetyl-CoA has two biosynthetic pathsCell Chemical Biology 29, 1–11, February 17, 2022 7
Figure 5. PfAcAS localizes to the nucleus and its inhibition affects histone acetylation state
(A and B) (A) Immunofluorescence localization of PfAcAS using an HA-epitope-expressing construct throughout the life cycle of the parasite. Shown are
representative images of early-, mid-, and late-stage trophozoite and schizont-stage parasites from a mixed-stage culture. PfAcAS-HA co-localized with DAPI
DNA stain throughout the majority of the parasite life cycle, consistent with nuclear localization of PfAcAS. (B) Schematic representation of the proposed function
of PfAcAS in the maintenance of acetyl-CoA available for histone acetylation by histone acetyltransferases (HAT), from free acetate generated by the activity of
histone deacetylases (HDAC).
(C) Dose-dependent reduction of histone acetylation by MMV019721 in wild-type 3D7 parasites but not in PfAcAS-T648M carrying drug-resistant parasites.
Shown are representative western blots of a single experiment.
(D) Dose-dependent reduction in histone acetylation byMMV019721 in Dd2 parent and not in A597Vmutant parasites. Shown are representative western blots of
a single experiment.
See also Figures S6 and S7.
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prevention, Cell Chemical Biology (2021), https://doi.org/10.1016/j.chembiol.2021.07.010via a mitochondrial branched-chain keto acid dehydrogenase
(BCKDH) complex or via acetyl-CoA synthetase (Cobbold et al.,
2013). Our study and the work of Schalkwijk et al. (2019) demon-
strate that PfAcAS activity is essential, implying that acetyl-CoA
derived from the BCKDH pathway cannot compensate for loss
of PfAcAS activity.
Mammalian orthologs of PfAcAS have been shown to play a
critical role in the regulation of epigenetic function, including in
metabolic switching of cancer cells in response to anoxic stress,
and in hippocampal cells associated with memory retention (Bu-
lusu et al., 2017; Comerford et al., 2014; Li et al., 2017a, 2017b;8 Cell Chemical Biology 29, 1–11, February 17, 2022Mews et al., 2017). Elegant work in yeast demonstrates the crit-
ical role for nuclear-localized acetyl-CoA synthetase in histone
acetylation and the correlation with cell viability (Takahashi
et al., 2006). There are relatively few transcription factors in the
P. falciparum genome, and it has been suggested that epigenetic
regulation may play an integral role in cell-cycle regulation in
Plasmodium (Templeton et al., 2004; Balaji et al., 2005; Hollin
et al., 2020). Recently, PfAcAS has been identified as a
putative member of a chromatin remodeling complex that is
associated with the promoter region of highly transcribed genes,
which also coincides with enrichment of H3K9 acetylation
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function could suggest a unique role in linking the metabolic
state of the cell to epigenetic regulation in the parasite, and high-
lights enzymes involved in epigenetic regulation as an attractive
target for antimalarial drug discovery.
It is interesting to note that, in a small subset of clones, muta-
tions in the acyl-CoA synthetase PfACS11 were associated with
low-level resistance to MMV019721. Mutations in this gene have
previously been found in association with PfAcAS mutations in
parasites selected for resistance to the coenzyme A anti-metab-
olite-forming pantothenamides (Schalkwijk et al., 2019). Another
study has also identified ACS11 as a potential resistance medi-
ator to unrelated antiplasmodial compounds (MMV019719 and
MMV665924) (Cowell et al., 2018). Conditional knockdown of
ACS11 had no effect on parasite susceptibility to MMV019721
or MMV084978, and mutations in ACS11 did not localize to
any clear functional domains within the protein, suggesting
that ACS11 is not a primary target of these compounds.
Together, the results of these studies suggest that ACS11 may
be a mediator of resistance, but further experimental work will
be needed to define the ACS11 function.
The work presented here clearly identifies PfAcAS as the
target of the small-molecule inhibitors MMV019721 and
MMV084978. Single mutations in the gene are sufficient to
confer resistance both in cell culture and when purified enzymes
are profiled in vitro. Together, these observations provide good
support for inhibitor potency having a direct effect on drug sus-
ceptibility in the parasite, and bodes well for medicinal chemistry
efforts. Cytotoxicity studies in HepG2 cells and in vitro enzymatic
assays testing the human ortholog HsACSS2 showed the
potential for high selectivity between the parasite and host en-
zymes, increasing the promise of this target for antimalarial
drug development. A working model for the mechanism of killing
is that inhibition of PfAcAS results in disruption of acetyl-CoA
recycling in the nucleus leading to a reduction in histone acety-
lation. This, in turn, dysregulates the epigenetic program of the
tightly controlled gene expression in P. falciparum and causing
cell death.
SIGNIFICANCE
Malaria is a global disease, which results in more than 200
million infections each year, and kills in excess of 300,000
people every year, predominantly children and pregnant
women. The emergence and spread of drug resistance pla-
ces many of the frontline antimalarials currently in use at
risk, and there is an urgent need to refresh the antimalarial
arsenal. Many of the antimalarial candidates currently under
development act against a relatively narrow range of para-
site targets, are susceptible to drug resistance via common
pathways, or are only active against blood stages of the
parasite. To support the goal of malaria control and eradica-
tion, it is crucial to identify new drug targets that have
activity against multiple stages of the parasite, and thereby
provide chemoprotective or transmission-blocking effects
in addition to therapeutic activity. For these reasons, the
identification and validation of novel druggable targets,
particularly those important at multiple stages of parasite
development, is a key priority for the field. Here, we appliedan array of chemogenomic, metabolomic, genetic, and
biochemical approaches to identify and validate the para-
site’s acetyl-CoA synthetase (PfAcAS) as the target of two
compounds (MMV019721 and MMV084978) active against
both liver and blood stages of the parasite. We also present
evidence that PfAcAS inhibitors disrupt the regulation of his-
tone acetylation, suggesting that PfAcAS may represent an
Achilles heel in the epigenetic regulation of parasite gene
expression. Together, these studies validate PfAcAS as a
drug target suitable for malaria chemoprevention and treat-
ment and provide a set of tools to support the target-based
identification of novel and selective PfAcAS inhibitors.
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Data and code availability
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work is supported by NIH grant U2C-DK119886.. This paper does not report original code. Any additional information required to
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Parasite cell lines and culture
The 3D7-A10 clone has been used in previous in vitro drug selection and sequencing efforts (Cowell et al., 2018). Dd2 parasites were
obtained from T.Wellems (NIAID, NIH). Dd2-B2 is a genetically homogeneous line that was cloned from Dd2 by limiting dilution in the
Fidock lab. Parasite strains were cultured in 3-5% humanO+ hematocrit in RPMI 1640 (Life Technologies) supplemented with 28mM
NaHCO3, 25 mM HEPES, and hypoxanthine (50 mg/mL). Depending on the parasite line, the media either contained gentamycin
(25 mg/mL), or no antibiotic and was additionally supplemented with 0.5% AlbuMAX II (Life Technologies) and/or O+ human serum
(heat inactivated and pooled). Blood and serum products were obtained from Interstate Blood Bank. Cultures were maintained at
37C in 1.1%O2, 4%CO2, and 95%N2. Parasite populationswere synchronized by 5%sorbitol treatment (Lambros and Vanderberg,
1979).
Insect cell line and culture
Sf9 cells were propagated in Gibco Sf-900 II SFMmedia supplemented with 2mML-glutamine and 100 U/ml penicillin/streptomycin.
Sf9 cells were routinely maintained as shake flask cultures grown in 250 mL Nalgene Single-Use PETG Erlenmeyer flasks
(ThermoFisher Scientific) stirred at 135 rpm and 27C to a cell density of 15–20 3 105 cells ml1 and R95% cell viability.
METHOD DETAILS
Dose-response assay
For in vitro–selected lines, drug susceptibility was measured by SYBR Green I–based assay (Johnson et al., 2007; Smilkstein et al.,
2004). Ring-stage parasites were cultured for 72 hr at 1% hematocrit and 1% starting parasitemia in 384-well black clear-bottom
plates containing test compounds plated in triplicate in 12-point serial dilutions. Lysis buffer (0.16% w/v saponin, 1.6% Triton
X-100, 5 mM EDTA, and 20 mM Tris-HCl, pH 7.4) with SYBR Green I fluorescent dye (Invitrogen) was added, and fluorescence read-
ings were taken (excitation at 494 nm, emission at 530 nm). Alternatively, Dd2-B2 ring-stage cultures at 0.3% parasitemia and 1%
hematocrit were exposed for 72 hr to a range of ten drug concentrations that were 2-fold serially diluted in duplicates alongwith drug-
free controls. Parasite survival was assessed by flow cytometry on an Accuri C6 (BD Biosciences) using SYBR Green and
MitoTracker Deep Red FM (Life Technologies) as nucleic acid stain and vital dyes respectively. EC50 values were calculated using
a nonlinear regression curve fit in Prism Software version 8 (GraphPad).
Resistance selection
3D7-A10 or Dd2-B2 clones were expanded to 1.5x107 parasites per flask (3x 25 mL at 5% hematocrit, 4% parasitemia) and
exposed to 3xEC50 concentrations of MMV019721 until cultures were smear-negative (5–7 days). Cultures were then maintained
in the absence of drug until parasites were detected bymicroscopy (7–14 days), at which point parasite-positive flasks were split into
two cultures and exposed to higher concentrations of compound (6xEC50) until no impaired growthwas apparent, or weremaintained
in the absence of selection compound. Bulk cultures were tested for reduced drug susceptibility and individual clones were isolated
by limiting dilution. MMV019721 resistant bulk cultures and clones were genotyped by whole-genome sequencing and confirmed by
sanger-sequencing of the PfAcAS locus (amplified using SeqF1 and SeqR4 primers) and the following primer pairs: SeqF1 CAATGA
ATAATTTGAAGAGTTATGG, SeqR1: CTGGGAACAAATATTTAAATGG, SeqF2: GGATATGTGTGGAATGATACAAAC, Seq R2:
CCAGCTGTTGTATGTGCAAC, Seq F3: CCTGAACCTGATAAAAATAGCACAAGC, Seq R3 GAAATGAAACAACAGCTGCTTCAGC,
SeqF4 CAGCAGAAATTGAACATGCACTAGTTC, Seq R4 TAGCGTCTCGAGTTATTTCTTAATTTCAATATGCTTTAACTTTTTTTTACA.e3 Cell Chemical Biology 29, 1–11.e1–e8, February 17, 2022
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Infected RBCs were washed with 0.05% saponin and genomic DNA was isolated from the parasites using a DNeasy Blood and
Tissue Kit (Qiagen) according to the standard protocols. Sequencing libraries were prepared with the Nextera XT kit (Cat. No FC-
131-1024, Illumina) via the standard dual index protocol and sequenced on the Illumina HiSeq 2500 in RapidRun mode to generate
paired-end reads 100bp in length. Sequence data is available under BioProject Accession number: PRJNA684602 in the NCBI
Sequence Read Archive. Reads were aligned to the P. falciparum 3D7 reference genome (PlasmoDB v13.0) using the previously
described pipeline (Cowell et al., 2018). A total of 18 clones were sequenced to an average whole genome coverage of 52x, with
an average of 97% of reads mapping to the reference genome (Table S1). Following alignment, SNVs and INDELs were called using
GATK HaplotypeCaller and filtered according to GATK’s best practice recommendations (McKenna et al., 2010). Variants were an-
notated using a custom SnpEff database and further filtered by comparing those from resistant clones to the parent clone, such that
only amutation present in the resistant clone but not the sensitive parent clone would be retained. CNVswere identified by differential
Log2 copy ratio as described in the GATK 4 workflow. Briefly, read counts were collected across genic intervals for each sample.
Copy ratios were calculated after denoising read counts against a strain-matched Panel of Normals comprised of non-drug-selected
Dd2 or 3D7 parasite samples.
Metabolite extraction
The metabolite extraction protocol was performed as described elsewhere (Allman et al., 2016). Briefly, 1 mL of trophozoites that
were magnetically purified to a concentration of 13108 parasites/mL were placed into wells with 4 mL of RPMI 1640 media and al-
lowed to recover for one hour. A drug corresponding to the appropriate condition was added to each well to a final concentration of
10-fold above the EC50 of that compound. The culture was incubated for another 2.5 hr. The culture was centrifuged and quenched
with 90%methanol containing 0.25 mM 13C,15N-Labeled-Aspartate, vortexed, and centrifuged. The supernatant was transferred to a
new tube and dried for storage. Prior to analysis, the samples were resuspended to a final concentration of 13108 parasites/mL in a
solution of 3% methanol:water containing 1 mM chlorpropamide as an internal standard.
Metabolomics LC/MS analysis
The chromatographic conditions used in this experiment were performed with slight modifications from previous methods
(Zhang et al., 2018). Briefly, a Waters XSelect HSS C18 column was used on a gradient reverse-phase chromatographic
configuration with 97:3 water:methanol with 10 mM tributylamine and 15 mM acetic acid (solvent A) and methanol
(solvent B). A Thermo-Scientific Exactive Plus Orbitrap mass spectrometer was operated in negative mode for the detection
of the metabolites. Peak picking and integration were performed using El-Maven LC/MS data processing software. The peak
data were then exported to Excel where metabolite areas were normalized to the internal standards, blank subtracted, and
averaged by condition.
Homology modeling studies
Homology models of PfAcAS and PfACS11 were prepared using the I-TASSER pipeline (Yang and Zhang, 2015; Zhang et al., 2017)
based on the solved Cryptococcus neoformans H99 structure for PfAcAS (PDB:5U29) and the solved structure of the adenylation
domain of carboxylic acid reductase of Nocardia iowensis in the adenylation conformation for PfACS11 (PDB:5MSD) (Gahloth
et al., 2017). Hydrogen atoms were added to each model and Gasteiger charges calculated using AutoDockTools 1.56. Images
were rendered using PyMOL 2.2.3 (Schrödinger, Inc.).
CRISPR/Cas9 editing of PfAcAS
Mutant PfAcAS-A597V and PfAcAS-T648M parasites were generated using CRISPR/Cas9. The guide RNAs for PfAcAS-A597V
(50-GTTGTGTAGCAGATATAGGT-30; 50-GCAGATATAGGTTGGGTTAC-30) and for PfAcAS-T648M (50-ATTAATGCTCTTAAGG
CTGT-30) were designed using Benchling (https://benchling.com/) to targeting sites in PfAcAS that were 6-14 bp upstream of the
A597 codon and 6 bp downstream of the T648 codon respectively. Complementary oligos encoding the gRNA sequences
(50- tattGTTGTGTAGCAGATATAGGT-3’ / 5’-aaacACCTATATCTGCTACACAAC-3’; 5’-tattGCAGATATAGGTTGGGTTAC-3’ / 5’-aa
acGTAACCCAACCTATATCTGC-3’ and 5’- tattgATTAATGCTCTTAAGGCTGT-3’ / 5’-aaacACAGCCTTAAGAGCATTAATc-3’ ) were
phosphorylated using T4 polynucleotide kinase and annealed (95C for 5 min, then step down of 5C/min to 25C) prior to ligation
into the BbsI-digested pDC2-coCas9-U6.2-hDHFR plasmid (Lim et al., 2016). The donor template for PfAcAS-A597V was synthe-
sized (ThermoFisher) as a 700 bp Genestring fragment spanning position 1468 to 2168 of the PfAcAS gene, and the donor for
PfAcAS-T648M synthesized as a 829 bp fragment spanning position 1468 to 2297 and inserted into the AatII/EcoRI sites of the
pDC2-coCas9-gRNA-hDHFR plasmid by Gibson assembly. Ring-stage parasites (Dd2) at 5% parasitemia were transfected by elec-
troporation (BioRad Gene Pulser II at 0.310 kV and 950 mF) with 50 mg of each plasmid (plasmid 1: pDC2-coCas9-AcAS-A597V-
gRNA1-hDHFR, plasmid 2: pDC2-coCas9-gRNA2-hDHFR, or plasmid 3: pDC2-coCas9-AcAS-T648M-gRNA1-hDHFR), and para-
sites selected for 10 dayswith 2.5 nMWR99210 (Jacobus Pharmaceuticals), followed by removal of drug pressure. After confirmation
of editing in the bulk culture, clones were isolated by serial limiting dilution and confirmed by Sanger sequencing after PCR ampli-
fication from genomic DNA using forward primer 50-AACACTGACATGGTAAATAACG-30 and reverse primer 50-GAATGGTAAACTAG
CACATCCTGG-30 (for A597V) and 50-GACAGTGGAAATATCTCCGAAAT-30 (for T648M).Cell Chemical Biology 29, 1–11.e1–e8, February 17, 2022 e4
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We used CRISPR-Cas9 to modify the native PfAcAS locus and install the linear pSN054 donor vector (Nasamu et al., 2020) that in-
corporates a C-terminal V5 and 2xHA-tags, a 10x aptamer array, and the TetR-DOZI expression cassette containing the blasticidin S
deaminase gene, the reporter gene Renilla luciferase (RLuc), and the fusion proteins TetR-DOZI (Ganesan et al., 2016). The right ho-
mology region (RHR) was PCR amplified and inserted into pSN054 using the I-SceI restriction site. Fragments corresponding to the
left homology region (LHR) fused to the re-codonized 30-end of the gene (bp 2710–2991) as well as the target-specifying guide RNA
sequence were synthesized using the BioXP 3200 System (SGI-DNA) and cloned into pSN054 using restriction sites FseI/AsisI and
AflII, respectively. Donor vector generation was carried out via Gibson assembly, and the final construct was confirmed by restriction
digests and Sanger sequencing. Primers used in this study are listed in the key resources table.
Transfection into Cas9-and T7 RNA polymerase-expressing NF54 parasites was carried out by preloading erythrocytes with the
AcAS_pSN054 plasmid as described previously (Deitsch et al., 2001). Briefly, 50–100 mg of purified plasmid DNA were mixed with
human red blood cells in 0.2 cm cuvettes and subjected to 8 square wave electroporation pulses of 365 V for 1 ms each, separated
by 0.1 s. The DNA preloaded red blood cells were inoculated with schizont-stage parasites (e.g. NF54attB, NF54:pCRISPR) to
achieve starting parasitemias %1% in RPMI 1640 Complete media. Cultures were maintained in 500 nM anhydrotetracycline
(aTc; Sigma-Aldrich 37,919) and 2.5 mg/mL Blasticidin S (RPI Corp B12150–0.1). Emergence of transfectants was monitored via
Giemsa smears and RLuc measurements. Clonal parasites were obtained by limiting dilution (Rosario, 1981).
Immunoblotting of PfAcAS cKD parasites
PfAcAS conditional knockdown parasites were cultured with (50 nM) and without aTc and proteins were extracted after 72 hr via
saponin lysis and resuspension in parasite lysis buffer that consists of 4% SDS and 0.5% Triton X-114 in PBS. Protein extracts
were mixed with loading buffer containing sodium dodecyl sulfate (SDS) and dithiothreitol (DTT) and loaded onto Mini-PROTEAN
TGX Precast Gels (4–15% gradient) in tris-glycine buffer. Proteins were transferred to a polyvinylidene fluoride (PVDF) membrane
using the Mini Trans-Blot Electrophoretic Transfer Cell system according to the manufacturer’s instructions and blocked with
100 mg/mL skim milk in TBS/Tween. Membrane-bound proteins were probed with mouse anti-HA (1:3,000; Sigma H3663) and
rabbit anti-GAPDH (1:5,000; Abcam AB9485) primary antibodies, and anti-mouse (1:5,000; Thermo Fisher Scientific 62–6520) and
anti-rabbit (1:5,000; Cell signaling 7074S) horseradish peroxidase (HRP)-conjugated secondary antibodies. Following incubation
in SuperSignal West Pico Chemiluminescent substrate (Thermo Fisher Scientific PI34080), protein blots were imaged and analyzed
using the ChemiDoc MP System and Image Lab 5.2.0 (Bio-Rad).
Histone acetylation and Western blot assays
The effect ofMMV019721 treatment on histone acetylation was tested inwildtype 3D7-A10 and drug-selected 3D7-T648Mparasites.
Synchronous trophozoite-stage (24-32hr post-invasion) cultures at 3–5% parasitemia and 2% hematocrit in complete medium were
exposed to test compounds for 3 hr at 37C. PfAcAS inhibitors were tested at3, 5 and 10x the 72hr EC50 of the compound in wild-
type parasites (1, 2.5 and 5 mM for MMV019721 and 325, 540 and 1080 nM for MMV084978 respectively). Trichostatin A (TSA), a
non-specific HDAC inhibitor and atovoquone (ATQ) were equally active against wt and mutant parasites and were tested at single
concentrations corresponding to three times their EC50 (70 nM TSA and 7 nM ATQ). DMSO was tested at 0.1% as the vehicle-
only control. Following drug exposure, parasites were isolated via saponin lysis ice-cold 0.1% saponin in phosphate-buffered saline
(PBS). Isolated parasites were washed 3x in ice-cold PBS containing protease inhibitor cocktail (cOmplete mini, Roche) and lysed in
1x Laemmli Sample Buffer (Biorad) with 5% beta-mercaptoethanol (Sigma-Aldrich). Samples were heated at 99C for 10 min before
centrifugation. Equal quantities of solute were separated on Protean TGX Precast Gels (4–20% gradient) in Tris-SDS-glycine buffer,
transferred to nitrocellulose membrane by iblot (Invitrogen), and blocked for 1h in tris-buffered saline (TBS) with 5% skim milk pow-
der. Blocked membranes were probed with antibodies recognising tetra-acetylated H4 (H4ac4, Sigma-Aldrich 06–866), H4K8ac
(CST #2594), H3K9ac (CST #9649) or H3 (CST #4499), at 1:1000 dilution, and PfBiP (Shonhai et al., 2007) (at 1:5000 dilution) in
3%milk powder TBSwith 0.1%Tween 20 at 4Covernight andwith 800CWgoat a-rabbit IgG (Licor) at 1:10,000 dilution. Membranes
were visualised using a Licor Odyssey CLX imaging system and quantified using ImageJ.
Growth assay
To assess the growth of PfAcAS conditional knockdown parasites, synchronous ring-stage parasites were cultured in the presence
(50 and 3 nM) and absence of aTc and set up in triplicate in a 96-well U-bottom plate (Corning 62,406-121). Luminescence was
measured at 0, 72, and 120 hr post-invasion using the Renilla-Glo(R) Luciferase Assay System (Promega E2750) and the GloMax
Discover Multimode Microplate Reader (Promega). The luminescence values were normalized to chloroquine-treated (200 nM) sam-
ples and results were visualized on a scatterplot using GraphPad Prism (version 8; GraphPad Software).
Microscopy
Immunofluorescence assay (IFA) was carried out in solution as described (Tonkin et al., 2004). Cells were incubated with mouse
anti-HA primary antibody at 1:500 dilution for an hour followed by incubation with anti-mouse Alexa Fluor 488-conjugated secondary
antibody (Cell signaling 4408S) at 1:500 dilution. Cells were washed with PBS containing 0.5 mg/mL of DAPI before mounting onto a
microscope slide applied with ProLong Diamond Antifade Mountant (Thermo Fisher Scientific P36965).e5 Cell Chemical Biology 29, 1–11.e1–e8, February 17, 2022
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Facility at the Whitehead Institute and images were processed using ImageJ (Collins, 2007).
cKD compound susceptibility assays
Solutions of MMV019721 and MMV084978 were dispensed into 96-well U-bottom plates and serially diluted in complete medium to
yield final concentrations ranging from 0.003 to 1 mM and 0.006–1.6 mM, respectively. Synchronous ring-stage, aptamer-regulated
PfAcAS and control parasite lineswere resuspended in varying aTc concentrations (high = 50 nM, low = 1 nM, and no aTc) and distrib-
uted into the drug plate. DMSO carrier and chloroquine (200 nM) wells served as positive and negative controls. Luminescence was
measured after 72 hr as described above and EC50 values were obtained from corrected dose-response curves using
GraphPad Prism.
Protein expression and purification
Generation of PfAcAS bacterial expression plasmid. The gene encoding PfAcAS (UniProt ID C6KTB4) was codon optimised
for expression in Escherichia coli, chemically synthesized to contain NdeI and XhoI restriction sites and cloned by
Genscript (https://www.genscript.com) into the expression vector pET15b-TEV, a modified pET15b vector (Novagen) encoding
an N-terminal 6X-His tag followed by a tobacco etch virus (TEV) protease cleavage site to produce the bacterial expression clone
pET15b-PPT343.
Generation of PfAcAS baculovirus expression plasmid. The PfAcASORFwithin pET15b-PPT343 was excised and subcloned into a
pFastBac-HT (Invitrogen) vector modified to include NdeI and XhoI restriction sites. The resulting baculovirus expression clone
pFastBac-PPT358 was used as a plasmid template in a single PCR reaction containing mutagenesis primers to produce PfAcAS
A597V (pFastBac-PPT409) and PfAcAS T648M (pFastBac-PPT410) mutants. The expression clones pFastBac-PPT358,
pFastBac-PPT409 and pFastBac-PPT410 were separately transformed into E. coli DH10Bac (Invitrogen), and plated on LB agar
plates containing appropriate concentrations of kanamycin, gentamycin, tetracycline, X-gal and IPTG as per themanufacturer’s pro-
tocol. White colonies were selected and recombinant PfAcAS Bacmid DNA isolated by Maxiprep system (Qiagen).
Transfection of Sf9 cells with PfAcAS Bacmids. The recombinant PfAcAS Bacmid DNA was transfected into Sf9 insect cells using
Insect GeneJuice Transfection Reagent (Novagen). For transfection, 8 3 105 cells mL1 were seeded in a Nunc 6-well cell culture
plate (ThermoFisher Scientific) and allowed to attach for at least 1 hr. The lipid reagent and Bacmid DNA were diluted separately
into 500 mL Gibco Sf-900 II SFM media (ThermoFisher Scientific) without antibiotics, combined (1 mL) and incubated for at least
45 min to form transfection mix (lipid–DNA complexes). The supernatant from the settled Sf9 cells was removed and the transfection
mix was gently pipetted over the cells. The cells were incubated for 24 hr at 27C. After 24 hr, 1 mL of Sf-900 II SFM media with an-
tibiotics was gently added to the cells and continued incubation at 27C for another 6 days. The supernatant containing recombinant
baculovirus was harvested as passage 0 (P0) virus stock. 50mL of exponentially growing Sf9 cells (153 105 cells mL1) were infected
with 0.125 mL of P0 virus and incubated with shaking at 135 rpm at 27C for 3 days. The supernatant was P1 virus stock. The above
procedure was repeated to prepare P2 virus stock. All recombinant baculovirus stocks were preserved in the dark at 4C.
Baculovirus expression of PfAcAS protein in Sf9 cells. For test expression of wild type PfAcAS, PfAcAS A597V and PfAcAS T648M
mutants, 50 mL of exponentially growing Sf9 cells (153 105 cells mL1) were grown in three 250 mL Erlenmeyer flasks and infected
with recombinant baculovirus by the direct addition of 1%, 3%and 5% (v/v) P2 virus stock. A time course (e.g., 24, 48 and 72 hr) study
was performed to optimise expression levels and the time for harvest (i.e., R80% cell viability). Samples at each time point were
analyzed by SDS-PAGE to check expression level and the three PfAcAS proteins were identified by Western blot analysis using
anti-His antibody and HRP-conjugated secondary antibodies/chemiluminescence (Pierce) to detect the N-terminal His-tag in
PfAcAS, PfAcAS A597V and PfAcAS T648M. For large scale expression, Sf9 insect cells (15 3 105 cells mL1) were grown in 2L
Erlenmeyer flasks, infected directly with 1% (v/v) P2 virus stock and cultured at 27C with shaking at 135 rpm for 72 hr. Infected
Sf9 cells were spun down by centrifugation at 1000g for 10 min, washed in 1X PBS buffer and harvested by centrifugation at
1000g for 10 min. The cell pellets were stored at 20C until further use.
PfAcAS protein purification. The His-tagged PfAcAS, PfAcAS A597V and PfAcAS T648M were purified by metal affinity chroma-
tography followed by gel filtration chromatography (Figure S4A). Protein purifications were done at room temperature. The Sf9 cell
pellets were resuspended in buffer A (20 mM Tris-HCl pH 7.2, 200 mM NaCl) supplemented with DNAse and Proteoloc protease in-
hibitor cocktail (Expedeon). Cells were lysed using a continuous cell disruptor (Constant System) at 30 kpsi within a pre-cooled cham-
ber. The lysate was cleared by centrifugation at 40,000g for 30 min at 4C and the supernatant filtered through 0.2 mm filter. Cleared
lysate was loaded onto a 5 mL HisTrap HP column (GE Healthcare) pre-equilibrated with buffer A. The column was washed in two
steps with 10 column volumes of buffer A containing 25 mM and 40 mM Imidazole respectively. Proteins were eluted in a linear
gradient of 16-100% buffer B (20 mM Tris-HCl pH 7.2, 200 mM NaCl, 250 mM Imidazole; or 500 mM NaCl, 500 mM Imidazole for
PfAcAS A597V) over 20 column volumes. At each purification step, samples were analyzed by SDS-PAGE. The eluted protein
was dialyzed against buffer A overnight, concentrated using Jumbosep Centrifugal Device (Pall) and loaded onto a Superdex 200
26/60 gel filtration column (GE Healthcare) pre-equilibrated with buffer A. The peak protein fractions were pooled and concentrated
up to 0.5 mg/mL (PfAcAS A597V & PfAcAS T648M) or 10 mg/mL (PfAcAS wt) and stored at80C until further use. The purified pro-
teins were analyzed by SDS PAGE (2mg) for densitometry, analytical GF (Superdex 200 increase 10/30) (Cytiva) calibrated with stan-
dards (BioRAD) and peptide mass fingerprinting using Mass Spectrometry.Cell Chemical Biology 29, 1–11.e1–e8, February 17, 2022 e6
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The gene encoding HsAcAS (cytoplasmic) gene (Genebank AF263614.1) containing an N-terminal His tag and TEV site was synthe-
sized by GenScript and cloned into pCDNA 3.1 vector, using Nhe1 and Xho1 restriction sites. The plasmid was transformed into XL1
cells then a maxiprep was carried out.
A transfection into the Expi293 was carried out as described in the Expi293 Expression System user guide (Thermofisher). Briefly
1 mg/mL of plasmid DNAwas transfected permL of transfection. A total volume of 1000mLwas transfected (23 500mL in 2L dispos-
able vented shake flasks). The cells were harvested by centrifugation at 1000 g for 10 min. The pellets were then washed in PBS then
centrifuged again. The pellet was stored at 20C until purification. The resulting pellet weight was 37g. For lysis 150 mL of 25 mM
Bicine pH 7.6/0.1% Triton/150 mMNaCl containing Proteoloc Protease inhibiter EDTA Free (AbCAM) and DNase (Sigma) was added
to the pellet. This was then heated at 25C for 20 min in a water bath to defrost. The cells were resuspended then lysed using a Con-
stant Cell Disrupter (Constant Systems) at 30 KPSI. The lysate was then centrifuged at 40,000 g for 20 min. The supernatant was then
diluted 1:3 in 25 mM TRIS pH 8.5/500 mM NaCl/20 mM Imidazole/0.5 mM TCEP (Buffer A) then filtered with a VacuCAP 90 Pf Filter
0.8/0.2 (Pall). The supernatant was loaded at 5 mL/min onto a 5 mL HiTrap His column (Cytiva) on an AKTA Pure system at 2–8C. A
10CV wash of buffer A was then carried out followed by a 5% Buffer B (A+500 mM Imidazole) wash for 7 CV to remove His rich
nonspecific binding proteins. A gradient of 5-50% B over 20CV was used to elute the protein. Following SDS PAGE the peak was
pooled and quantified. This showed 35 mgs of the HsAcAS protein. This was dialyzed into 3 x 1L of 25 mM TRIS pH 8.5/150 mM
NaCl/10% Glycerol/0.5 mM TCEP(Buffer C) to remove the imidazole. The protein was concentrated using a Macrosep 10kDa
Advance concentrator (Pall) to 10.5 mL for loading onto an XK26/60 Superdex 200 Gel Filtration column (Cytiva) at 2 mL/min. The
protein eluted as a single monomeric peak (Figure S4B). The protein was then concentrated to 15.5 mg/mL using a Macrosep
10kDa Advance concentrator then snap frozen in liquid nitrogen and stored at 80C. The final yield was 15.5 mgs from a 1L Trans-
fection. The protein was then analyzed by SDS PAGE (2mg) for densitometry, analytical GF (Superdex 200 increase 10/30) (Cytiva)
calibrated with standards (BioRAD), Nanotemper Tycho and peptide mass fingerprinting using Mass Spectrometry.
PfAcAS EnzChek kinetic measurements
Steady-state kinetic measurements were conducted at room temperature using a PheraStar plate reader (BMG). The first step of the
reaction ofPfAcAS, which produces inorganic pyrophosphate (PPi) that is converted to twomolecules of inorganic phosphate using a
pyrophosphatase enzyme, was continuouslymonitored using the EnzChek Phosphate Assay Kit, which gives an absorbance readout
at 360 nm (Figure 4A) (Webb, 1992). As demonstrated by Noy, T. and colleagues, the product AcAMP remains tightly bound to the
active site in the absence of CoA (Noy et al., 2014), stopping the reaction, resulting in no changes in the signal for the first step, the rate
limiting step (Noy et al., 2014), even in the presence of acetate and ATP. By adding CoA, the reaction rapidly proceeds to the second
step resulting in further release of pyrophosphate, making the EnzChek assay a suitable option to continuously monitor the activity of
PfAcAS. Typical kinetic assays were carried out in clear, flat-bottom, polystyrene, 384-well plates (Greiner) in an 80 mL reaction
volume containing 100 mM HEPES (pH7.4), 100 mM NaCl, 250 mM KCl, 50 mM MgCl2, 1 mM DTT, 0.004% Tween 20, 0.5 U/mL
pyrophosphatase, 0.1 mM MESG, 0.5 U/mL PNP, 2 mM ATP, 2 mM acetate, 0.5 mM CoA and 5 nM recombinant PfAcAS WT or
10 nM recombinant PfAcAS A597V or T648M. Assays were performed by adding 40 mL of a 2-times concentrated substrate mixture
includingMESG to all wells, and the reactions started by adding 40 mL of a 2-times concentrated reaction mixture containing all other
components. The reactions were carried out for 2 to 4 hr with absorbance readings at 360 nm every two to four minutes. Reaction
rates were extracted from the linear phase of activity, usually using 10 to 20 points between times of 30 and 100 min of the reactions.
Using a phosphate standard curve obtained under the same buffer conditions used for the PfAcAS reactions (Figure S5A), the rates
were then converted to velocity per second, conversion of one nanomolar of phosphate, per nanomolar of enzyme, per second. The
substrates Km values were determined by varying the concentration of one of the substrates at saturating concentration of the other
two substrates. Steady-state data were fitted using the nonlinear, least-squares, curve-fitting programs of Sigma-Plot for Windows,





where V is the maximal velocity, S is the substrate concentration and K is the Michaelis constant for the substrate (Km). Individual








where Ks is the substrate inhibition constant.
PfAcAS mode of inhibition studies
Using the EnzChek assay platform, the IC50 values for MMV019721 and MMV084978 were determined at saturating concentrations
of all three substrates, 2 mM ATP, 2 mM acetate and 0.5 mM CoA, in a series of 10, one in three dilutions, of the inhibitors. To deter-
mine the steady-state inhibition parameters and patterns associatedwith both inhibitors,PfAcAS activity was studied in the presence
of variable concentrations of one substrate, ATP, acetate or CoA, fixed saturating concentration of the other two substrates (acetatee7 Cell Chemical Biology 29, 1–11.e1–e8, February 17, 2022
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concentrations of inhibitor were prepared using an Echo 550 acoustic dispenser (Labcyte Inc.). The assays were carried out as
described in the previous section. Inhibition data obtained under saturating concentrations of substrates, and variable concentration
of MMV019721 or MMV084978 were fit to Equation 3







where ymin corresponds to no inhibition and ymax to maximum inhibition, IC50 is the concentration of inhibitor necessary to give
50% inhibition and I is the inhibitor concentration. For better comparison between both inhibitors and proteins, the ymin was











where Ki is the dissociation constant for the enzyme-inhibitor complex. Inhibition data showing linear, mixed inhibition patterns in













where Kis is the dissociation constant for the free enzyme-inhibitor complex and Kii is the dissociation constant for the enzyme-sub-








HsAcAS rapid-Fire QQQ assays
The human form of acetyl-CoA synthetase was assayed in 100mMHEPES (pH7.4), 100mMNaCl, 250mMKCl, 50 mMMgCl2, 1 mM
DTT, 0.005%NP40, 400 mMATP, 70 mMacetate, 40 mMCoA and 2 nM recombinantHsAcAS. Assay ready plates containing different
concentrations of inhibitor were prepared using an Echo 550 acoustic dispenser (Labcyte Inc.), dispensing 150 nL of compound per
well. Assays were conducted in a total volume of 15 mL for 30 min at room temperature before being quenched with the addition of
85 mL 1% formic acid containing 0.5 mg/mL n-Propionyl coenzyme A (Sigma P5397) as an internal standard. Reaction products were
detected using a RapidFire 365 system (Agilent, Santa Clara, CA) coupled with a triple quadrupole mass spectrometer 6740 (Agilent).
The samples were loaded onto a D-hypercarb cartridge (Agilent) using deionized water at a flow rate of 1.5 mL/min and eluted to
the mass spectrometer using 5 mM ammonium acetate in deionized water/acetonitrile/acetone (proportions of 2/1/1, v/v) at a flow
rate of 1.25 mL/min. The sipper was washed to minimize carryover with 0.1% TFA in deionized water followed by 0.1% TFA in aceto-
nitrile/deionized water (95%/5%, v/v). The sipper was washed to minimize carryover with deionized water followed by acetonitrile.
Aspiration time, load/wash time, elution time, and re-equilibration time were set to 600, 3000, 5000, and 500 ms, respectively, with a
cycle time of approximately 10 s. The triple-quadrupole mass spectrometer with electrospray ion source was operated in positive
multiple reaction monitoring (MRM) mode. The detailed setting for the mass spectrometer parameters was as follows: capillary
voltage, 3000 V; gas temperature, 350C; gas flow, 7 L/min; nebulizer, 40 psi; sheath gas temperature, 300C0 sheath gas flow,
11 L/min; and nozzle voltage, 1500 V. The MRM transitions for acetyl-CoA as a reaction product were set as 810.1/303.1 &
810.1/428.1 (quantifier & qualifier with dwell time of 50 ms, 100V fragmentor, and collision energies of 30 & 28 eV respectively)
and for n-propionyl-CoA as an internal standard as 824.2/317.2 & 824.2/428.0 (quantifier & qualifier with dwell time of 50 ms,
100V fragmentor, and collision energies of 32 & 26 eV respectively). The mass resolution window for both parental and daughter
ions was set at as a unit (0.7 Da). Peak areas were integrated, and area ratios of acetyl-CoA to the internal standard (n-propionyl
CoA) were used for quantitation. Data were converted to % inhibition relative to the uninhibited enzyme control and fitted to
Equation 3.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data analyses were performed with GraphPad Prism (v8.0) and R (v3.6.1). Data shown in figures are averages of at least 2 replicates
with standard deviation, or are representative results of individual experiments. p values were stated in the figure legends. Sample
size and statistical tests are also reported in the figure legends.Cell Chemical Biology 29, 1–11.e1–e8, February 17, 2022 e8
